摘要
1型和2型糖尿病患者的骨质量受损,骨折风险升高。由于糖尿病患者的骨密度不一定下降,而且各种糖尿病治疗有可能对骨骼产生影响,因而给临床上如何管理糖尿病患者的骨折风险带来了挑战。中华医学会骨质疏松和骨矿盐疾病分会、中华医学会内分泌学分会、中华医学会糖尿病学分会和中国医师协会内分泌代谢科医师分会共同组织专家,在充分汇总复习文献的基础上,就如何在糖尿病患者中评估骨折风险、实施骨质疏松防治、合理使用各类降糖药物等问题达成共识。
Both type 1 and type 2 diabetes are at increased risk of fractures. However, the bone mineral densities in diabetic patients are not always declined, and diabetes therapies may also have various impacts on bone, thus leading to a clinical challenge on the management of the fracture risk in diabetic patients. After a full review of the most recent evidence, experts from Chinese Society of Osteoporosis and Bone Mineral Research, Chinese Society of Endocrinology, Chinese Diabetes Society, Chinese Medical Association, and Chinese Endocrinologist Association, Chinese Medical Doctor Association reached a consensus on several issues relating to how to evaluate fracture risk, when to initiate anti-osteoporosis therapies, and how to optimally use antidiabetic agents in diabetic patients.
作者
无
刘建民
朱大龙
母义明
夏维波
Liu Jianmin;Zhu Dalong;Mu Yiming;Xia Weibo(Chinese Society of Osteoporosis and Bone Mineral Research,Chinese Medical Association;Chinese Society of Endocrinology,Chinese Medical Association;Chinese Diabetes Society,Chinese Medical Association;Chinese Endocrinologist Association,Chinese Medical Doctor Association;Department of Endocrine and Metabolic Diseases,Ruijin Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200025,China;Department of Endocrinology,Nanjing Drum Tower Hospital Affiliated to Nanjing University Medical School,Nanjing 210008、China;Department of Endocrinology,the General Hospital of Chinese People's Liberation Army,Beijing 100853,China;Department of Endocrinology,Peking Union Medical College Hospital,Chinese Academy of Medical Science,Beijing 100730,China)
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
2019年第7期535-547,共13页
Chinese Journal of Endocrinology and Metabolism
关键词
糖尿病
骨折
骨密度
骨质量
治疗
Diabetes
Fracture
Bone mineral density
Bone quality
Treatment
